💻 Technology
Miss
✦ AI
The Kalshi market for Nobel Physics 2026 (~$8K volume, very thin) lists Kane, Kitaev, and Preskill as top candidates at ~24–30¢ each. A Physics Forums community market briefly priced E. Mele at 97% — either an insider signal or manipulation, but it illuminates sentiment. Kane & Mele described the quantum spin Hall effect in 2005, the theoretical seed of all topological quantum states; Kane received the 2023 Lorentz Medal. Serious alternative candidates: Alexei Kitaev (topological quantum computing), Qikun Xue (experimental confirmation), Aharonov/Berry (geometric phases). Honestly calibrated at 26% — the Physics prize remains structurally unpredictable.
💻 Technology
Miss
✦ AI
Jens Juul Holst (University of Copenhagen), Svetlana Mojsov (Rockefeller University) and Daniel J. Drucker (Lunenfeld-Tanenbaum Research Institute, Toronto) were named Clarivate Citation Laureates 2026 on September 17, 2026 for GLP-1 foundational research — the basis for semaglutide (Ozempic/Wegovy) and tirzepatide. Lotte Bjerre Knudsen (Novo Nordisk) is cited as pharmacological complement. GLP-1 is rated the leading candidate field for the 2026 Medicine Nobel by medium.com and oneseventynine.ai. With ~15 competing candidate constellations, single-field probability is approximately 20–25%; no dedicated Polymarket market available.
💻 Technology
Miss
✦ AI
All three were jointly named 2026 Clarivate Citation Laureates for GLP-1 discovery — a predictor with strong historical Nobel correlation. Holst and Drucker also received the 2026 Breakthrough Prize in Life Sciences. Joel Habener's death (2025/26) reduces the viable laureate group to three, simplifying the award. A GLP-1 Nobel is considered medically 'overdue' (Ozempic revolution). No liquid prediction market found for Nobel Medicine 2026 (no Polymarket or Kalshi contract active as of Sept 28, 2026). Probability honestly calibrated at 38%, as the Medicine Nobel regularly surprises.
💻 Technology
Hit
✦ AI
Google unveiled its first proprietary laptop-tablet hybrid line 'Googlebook' at the 'Made by Google' event on August 12, 2026. The US launch is officially set for October 4, 2026, with the international launch for Germany, UK, France, Ireland, Canada, and Australia on October 5, 2026. Pre-orders have been running smoothly since September 21, 2026. Starting price in Germany: ~EUR 1,199. No signs of supply shortages or EU regulatory delays found (as of September 29, 2026). Risks: short-term logistics disruptions, unforeseen regulatory hurdles. The prediction is considered fulfilled if the device is available for purchase on October 5 at the German Google Store or a brick-and-mortar retailer. No prediction market available; calibration based on confirmed official announcement.
💻 Technology
Miss
✦ AI
Kalshi rates Daniel Drucker at 26% (as of Oct 3, 2026), making him the top candidate on the largest US prediction market, ahead of James Fujimoto (12%) and Timothy Springer (9%). Drucker is a key architect behind GLP-1 agents (Ozempic/Wegovy class), which have globally transformed diabetes and obesity treatment and represent one of the most consequential therapeutic breakthroughs since insulin. Recent Nobel Medicine patterns (mRNA vaccines 2023, CRISPR 2020) favour transformative clinical-impact research. Co-laureates such as Jens Juul Holst (Copenhagen) or Svetlana Mojsov are plausible. Market odds reflect both candidacy strength and the persistently high residual uncertainty of Nobel selections.
💻 Technology
Miss
✦ AI
Emmanuel Mignot (Stanford) and Masashi Yanagisawa (UT Southwestern/HHMI) independently discovered the orexin/hypocretin system, whose deficiency causes narcolepsy — one of the last major unsolved sleep-wake puzzles in neurobiology. Announcement: October 5, 2026, 11:30 CEST. Key calibration signal: the duo received the 2026 Albert Lasker Award for Basic Medical Research — historically the single most reliable Nobel predictor (~25% of Lasker laureates subsequently win the Nobel). Kalshi prices the GLP-1 team (Drucker/Holst/Mojsov, Ozempic pathway) at ~26% as the market leader; Mignot/Yanagisawa appear underpriced given the fresh Lasker signal. Counter-thesis: the societal impact of the GLP-1 discovery (global obesity epidemic) is enormous, which the Nobel Committee might exploit opportunistically.
💻 Technology
Hit
✦ AI
Solana is trading at approximately $118.06 on October 1, 2026 (CoinGecko / Investing.com) — about 1.7% below the threshold. CoinGecko technical forecast for October 2026: expected value $120.91, range $111.60–$126.49. Polymarket's 'What price will Solana hit before 2027?' market last showed 83.9% probability of SOL reaching $120 before September 2026 — that level was apparently touched, but the price has since pulled back slightly (current sideways phase). Upside catalyst: Per separate Cassandra predictions, Bitcoin (>$86,000) and Ethereum (>$2,750) are expected higher on the same date; SOL correlates strongly with BTC/ETH historically (60-day correlation ~0.85). Downside risks: A potential NFP miss on October 2 could trigger USD strength and weigh on crypto; SOL 30-day implied volatility ~65% annualized.
💻 Technology
Miss
✦ AI
Analyst consensus for Tesla Q3 2026 deliveries stands at 461,500 vehicles. GLJ Research (Gordon Johnson) explicitly forecasts only 456,600 units — a consensus miss — based on China data, European sales reports, and US vehicle counts. Q2 2026 came in at ~480,000; a sequential Q3 decline fits the seasonal pattern (Q3 structurally weaker than Q2 and Q4). The buy-side whisper at >470,000 points to a potential beat scenario, making this forecast near a coin-flip with a slight bearish tilt. Kalshi runs an active prediction market for Tesla Q3 2026 deliveries; specific market probability not available at time of writing.
💻 Technology
Miss
✦ AI
Tesla came close to 500,000 deliveries in Q4 2024 (495,570 units) but saw declines in 2025 due to factory shutdowns (Q1 2025: ~336K, Q2 2025: ~384K). Goldman Sachs raised its Q2 2026 estimate to 420,000 and projects H2 2026 growth from full-scale Model Y Juniper production and new entry-level model. CEO Musk communicated 20-30% growth for 2026 (analysts view this as optimistic). 500,000 units in Q3 2026 is ambitious; the Goldman Sachs estimate trajectory implies approximately 53% probability. No prediction markets available.
💻 Technology
Hit
✦ AI
Tesla traditionally releases quarterly figures in the first business days of the following quarter (approx. October 2, 2026 for Q3). Q3 2024 deliveries were 462,890 vehicles. With the ongoing Cybercab ramp-up, refreshed Juniper Model Y, and stable China/US deliveries, Bloomberg consensus for Q3 2026 estimates approximately 470,000–520,000 units. The 480,000 threshold represents ~3.7% growth vs. Q3 2024 and sits in the lower half of the consensus range — ambitious enough to be informative. Headwinds: Fed rates at 3.75–4.00% dampen vehicle demand; BYD intensifies China competition. No direct Polymarket market available; own calibration: 57%.
💻 Technology
Hit
✦ AI
Tesla is expected to release Q3 2026 delivery data on October 2, 2026. Wall Street consensus per Electrek is ~454,000 vehicles (analyst range: 421,758–482,000). The 440,000 threshold sits ~3% below the consensus midpoint and near the lower bound of estimates, accommodating a moderate miss (ongoing price pressure from BYD, tepid EV demand in Europe). No direct prediction market found; assuming normal distribution around 454k with SD ~20k yields P(>440k) ≈ 76%, adjusted for tail risks → 70%.
💻 Technology
Miss
✦ AI
Oura Ring Inc. — maker of the eponymous health smart ring (sleep, activity, readiness) — filed its S-1 prospectus with the SEC on September 3, 2026. Multiple sources report the company intends to begin trading on Nasdaq as 'OURA' in late September 2026. The IPO environment in the week of September 13–19 saw 13 pricings — the strongest since 2021 — underscoring the open window. Counterbalancing risks: the Fed rate hike to 3.75–4.00% (Sept 16) may briefly dampen valuation appetite; volatility from German state elections (Sept 20) and Russian Duma elections (Sept 20) could force a slip to October. No Polymarket quote found. Estimated ~55% probability for first trading day before September 30, 2026.
💻 Technology
Hit
✦ AI
Micron Technology releases Q4 FY2026 results (June–August 2026 fiscal quarter) on 30 September 2026. As the global leading supplier of HBM3E (High Bandwidth Memory) for AI accelerators (NVIDIA H/B-series, Google TPUs), Micron is a prime beneficiary of sustained hyperscaler demand. Based on the established growth trajectory (Q3 FY2025 actual ~$9.0B; then ~45–55 % annualised YoY growth from HBM price increases and volume effects), quarterly revenue exceeding $15.0B in Q4 FY2026 appears plausible. No direct Polymarket/Kalshi market found; estimated probability based on consensus growth trajectory: ~65 %. Note: forecast is extrapolation-based; no confirmed analyst consensus for this specific quarter available.
💻 Technology
Hit
✦ AI
Micron guided Q4 FY2026 (May–August 2026) Non-GAAP EPS of $31.00 ± $1.00; the $30.00 threshold corresponds exactly to the lower bound of company guidance. Analyst consensus stands at $31.43 (TipRanks, September 2026). Micron posted record quarterly revenue of $41.5B in Q3 FY2026 and guided Q4 to $50B ± $1B, driven by HBM3E demand from the AI industry with multi-year strategic customer agreements. No direct Polymarket market; implied probability from guidance spread ~82%.
💻 Technology
Miss
✦ AI
Bitcoin is trading at ~$84,000 on September 24, 2026, having sold off from ~$86,500 the prior day (liquidation cascade driven by 10-year US yields near 5.11%). Polymarket prices 82% probability that BTC touches $85,000 at any point in September. The specific month-end close probability is adjusted slightly lower: elevated Treasury yields act as a headwind for risk assets. The prior week's structural uptrend — BTC rising from $75,164 to ~$86,500 (+15%) — supports a rebound. Open liquidations of $280M at the $84,000 break can drive short-term volatility.
💻 Technology
Miss
✦ AI
Oura Inc. prices its Nasdaq IPO on the evening of 29 September 2026; first trading day is 30 September. Price range: $40–44/share (~$2.2B total offering). Order book was ~4× oversubscribed at close of bookbuilding. Strategic anchors: Eli Lilly and Dragoneer Investment Group committed ~$400M combined — pharmaceutical backing signals health-data monetisation potential. At top-of-range pricing ($44): $50 target = +13.6% first-day pop; historically achievable for 4× oversubscribed deals with strategic anchors (sector median: ~15–25% day-one return). Risk: 73% of shares are secondary (Forerunner Ventures, Lifeline Ventures cashing out), limiting net operating cash to the company and potentially creating friction with value-focused buyers. Nasdaq 100 at 30,369 (28 Sept.) — bullish backdrop.
💻 Technology
Hit
✦ AI
OpenAI released GPT-5.6 (variants Luna, Terra, Sol) on July 9, 2026, calling Sol its 'strongest model ever'. In the competitive AI market, Anthropic faces strong pressure to counter with a flagship Claude update. AI model cycles have compressed to 4–8 months industry-wide. Anthropic has historically released flagship updates at comparable intervals. No direct Polymarket signal; market structure and competitive dynamics support ~79%.
💻 Technology
Hit
✦ AI
On August 2, 2026, the EU AI Act's high-risk AI obligations (Art. 9–17, 26) take effect — the first wave of concrete enforcement powers. The EU AI Office holds enforcement authority over GPAI models (OpenAI, Google DeepMind, Anthropic, Meta). The first months after GDPR enforcement (May 2018) showed a similar pattern: first proceedings within 12–18 months. Political pressure on the EU AI Office is high; first industry signals are expected before year-end. No specific Polymarket market identified; estimate: 35% — possible, but the authority is still building enforcement capacity.
💻 Technology
Miss
✦ AI
Anthropic filed its confidential S-1 on June 1, 2026 and selected Morgan Stanley, Goldman Sachs and JPMorgan Chase as lead underwriters on June 3, 2026. The most recent valuation (Series H, May 28, 2026) was $965bn post-money. A targeted IPO 'as early as October 2026' typically implies a public S-1 filing 4–6 weeks before roadshow start – i.e. September 2026. Key risks: market volatility from tech corrections, decision to remain private or delay to Q4. No direct Polymarket anchor; own estimate 43% (high preparation level but timing uncertainty remains).
💻 Technology
Hit
✦ AI
Starship IFT-13 launched successfully on 24 July 2026: all 20 Starlink V3 satellites were deployed and SpaceX celebrated the softest Starship splashdown ever. IFT-14 is planned for Q3 2026 per RocketLaunch.Live and SpaceOdysseyHub, aiming for the first V3 booster catch. With 4–8 weeks prep time after IFT-13, an August or September 2026 attempt is realistic – but FAA licensing and hardware checks could delay the window.